PMC:7306567 / 4303-6564
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 67 | 218-222 | Disease | denotes | CL-F | OMIM:102510 |
| 68 | 230-249 | Disease | denotes | infectious diseases | MESH:D003141 |
| 69 | 347-349 | Disease | denotes | PD | MESH:D010300 |
| 70 | 369-371 | Disease | denotes | LV | MESH:C535509 |
| 71 | 563-587 | Disease | denotes | invasive fungal diseases | MESH:D000072742 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T36 | 230-240 | Disease | denotes | infectious | http://purl.obolibrary.org/obo/MONDO_0005550 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T25 | 166-172 | http://purl.obolibrary.org/obo/UBERON_0007688 | denotes | fields |
| T26 | 218-220 | http://purl.obolibrary.org/obo/CLO_0052906 | denotes | CL |
| T27 | 257-259 | http://purl.obolibrary.org/obo/PR_000010213 | denotes | MB |
| T28 | 295-297 | http://purl.obolibrary.org/obo/CLO_0007706 | denotes | MH |
| T29 | 358-360 | http://purl.obolibrary.org/obo/UBERON_0003064 | denotes | IM |
| T30 | 407-409 | http://purl.obolibrary.org/obo/CLO_0008828 | denotes | RL |
| T31 | 456-458 | http://purl.obolibrary.org/obo/CLO_0007029 | denotes | JM |
| T32 | 456-458 | http://purl.obolibrary.org/obo/CLO_0050993 | denotes | JM |
| T33 | 722-723 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T34 | 764-765 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T35 | 829-834 | http://purl.obolibrary.org/obo/UBERON_0007688 | denotes | field |
| T36 | 949-950 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T37 | 1222-1223 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T38 | 1539-1541 | http://purl.obolibrary.org/obo/CLO_0053733 | denotes | 11 |
| T39 | 1544-1545 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
| T40 | 1638-1639 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
| T41 | 1831-1832 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T42 | 1921-1922 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T43 | 1942-1951 | http://purl.obolibrary.org/obo/OBI_0000245 | denotes | organizer |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T18 | 214-216 | Chemical | denotes | KL | http://purl.obolibrary.org/obo/CHEBI_74561 |
| T19 | 295-297 | Chemical | denotes | MH | http://purl.obolibrary.org/obo/CHEBI_74703 |
| T20 | 329-337 | Chemical | denotes | medicine | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T21 | 339-341 | Chemical | denotes | EA | http://purl.obolibrary.org/obo/CHEBI_73849 |
| T22 | 347-349 | Chemical | denotes | PD | http://purl.obolibrary.org/obo/CHEBI_74756 |
| T23 | 351-353 | Chemical | denotes | PW | http://purl.obolibrary.org/obo/CHEBI_74797 |
| T24 | 354-356 | Chemical | denotes | LL | http://purl.obolibrary.org/obo/CHEBI_73531 |
| T25 | 358-360 | Chemical | denotes | IM | http://purl.obolibrary.org/obo/CHEBI_74073 |
| T26 | 369-371 | Chemical | denotes | LV | http://purl.obolibrary.org/obo/CHEBI_73579 |
| T27 | 407-409 | Chemical | denotes | RL | http://purl.obolibrary.org/obo/CHEBI_73815 |
| T28 | 456-458 | Chemical | denotes | JM | http://purl.obolibrary.org/obo/CHEBI_31739 |
| T29 | 951-956 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
| T30 | 1009-1014 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
| T31 | 1142-1147 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T2 | 879-891 | http://purl.obolibrary.org/obo/GO_0009405 | denotes | pathogenesis |
| T3 | 1308-1316 | http://purl.obolibrary.org/obo/GO_0015297 | denotes | exchange |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T29 | 0-99 | Sentence | denotes | The expert panel is comprised of 29 participants from seven European countries, the USA and Taiwan. |
| T30 | 100-460 | Sentence | denotes | To ensure heterogenicity, participants were selected from various fields of expertise: medical microbiology (PEV, KL, CL-F, TRR), infectious diseases (BJAR, MB, TC, CJC, OAC, DRG, NAFJ, BJK, OL, MH-N, TFP, FLvdV), intensive care medicine (EA, SB, PD, PW-LL, IM-L, JAS, LV, JW), clinical pharmacology (RJMB, RL, IS), public health (TC) and hematology (OAC, JM). |
| T31 | 461-628 | Sentence | denotes | Selected participants furthermore had specific expertise in epidemiology, diagnosis and management of invasive fungal diseases or fungal disease guideline development. |
| T32 | 629-681 | Sentence | denotes | The meeting was prepared by PEV, RJMB, JW and FLvdV. |
| T33 | 682-754 | Sentence | denotes | Case definitions were developed through a process of informal consensus. |
| T34 | 755-1090 | Sentence | denotes | Although a systematic literature review was not performed, experts in the field presented overviews regarding epidemiology, pathogenesis, diagnosis and treatment of IAPA, which were followed by a group discussion process designed to allow members of the group to voice their opinions and contribute equally to the decision-making [12]. |
| T35 | 1091-1169 | Sentence | denotes | The goal of the consensus process was to bring the group to general agreement. |
| T36 | 1170-1355 | Sentence | denotes | Presentations and initial discussions took place on a single day meeting in April 2019 in Amsterdam and were continued through electronic exchange of views until consensus was achieved. |
| T37 | 1356-1543 | Sentence | denotes | The chosen framework included host and risk factors, clinical factors and mycological evidence, similar to the framework in the EORTC/MSGERC definitions and the AspICU algorithm [10, 11]. |
| T38 | 1544-1637 | Sentence | denotes | A medical writer made notes of the meeting, which were used as input to write the manuscript. |
| T39 | 1638-1754 | Sentence | denotes | A first draft manuscript was prepared by PEV, BJAR, RJMB, JW and FLvdV and circulated for comments from all experts. |
| T40 | 1755-1808 | Sentence | denotes | The experts reviewed and commented on the manuscript. |
| T41 | 1809-1875 | Sentence | denotes | Using these comments, a final version was circulated for approval. |
| T42 | 1876-2090 | Sentence | denotes | The logistics of the meeting were handled by a certified Congress organizer (Congress Care, s’Hertogenbosch, the Netherlands) with financial support of Pfizer (Pfizer B.V., Capelle aan den IJssel, the Netherlands). |
| T43 | 2091-2261 | Sentence | denotes | Congress Care and Pfizer had no influence on the selection of participants, selected topics, discussions, preparation and final approval of the content of the manuscript. |
LitCovid-PMC-OGER-BB
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T39 | 387-399 | CHEBI:52217;CHEBI:52217 | denotes | pharmacology |
| T40 | 572-578 | NCBITaxon:4751 | denotes | fungal |
| T41 | 591-597 | NCBITaxon:4751 | denotes | fungal |
| T42 | 744-753 | SO:0000993 | denotes | consensus |
| T43 | 1107-1116 | SO:0000993 | denotes | consensus |
| T68350 | 387-399 | CHEBI:52217;CHEBI:52217 | denotes | pharmacology |
| T21985 | 572-578 | NCBITaxon:4751 | denotes | fungal |
| T87756 | 591-597 | NCBITaxon:4751 | denotes | fungal |
| T42141 | 744-753 | SO:0000993 | denotes | consensus |
| T46351 | 1107-1116 | SO:0000993 | denotes | consensus |
2_test
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 32572532-10623041-47963399 | 1086-1088 | 10623041 | denotes | 12 |
| 32572532-22517788-47963400 | 1539-1541 | 22517788 | denotes | 11 |
| T46095 | 1086-1088 | 10623041 | denotes | 12 |
| T11193 | 1539-1541 | 22517788 | denotes | 11 |